Literature DB >> 1450094

Comparison of effects of enalapril and captopril on serum potassium concentration in the treatment of malignant hypertension.

T Tsuchihashi1, I Abe, A Tsukashima, K Kobayashi, M Ueno, M Fujishima.   

Abstract

To compare the effects of enalapril and captopril on blood pressure, serum creatinine (S-Cr), and potassium (S-K) levels, patients with malignant hypertension treated with either 5-10 mg of enalapril (eight cases) or 75-400 mg of captopril (eight cases) were investigated retrospectively. After 2 weeks of treatment, the average blood pressure fell from 214/138 to 132/89 mmHg on enalapril and from 240/145 to 147/95 mmHg on captopril. The percent change in mean blood pressure during the 2 weeks of treatment with enalapril (-35.6 +/- 4.0 SE%) was similar to that with captopril (-35.8 +/- 2.8%). S-Cr did not change in both groups, while S-K increased significantly from 3.9 +/- 0.2 to 5.2 +/- 0.2 mEq/l on enalapril and from 3.6 +/- 0.2 to 4.2 +/- 0.1 mEq/l on captopril. S-K at the second week was significantly higher in the enalapril than in the captopril group. The maximum S-Cr concentration during the treatment was correlated with the corresponding S-K concentration similarly in both groups. These results indicate that both enalapril and captopril increase S-K without deterioration of renal function in patients with malignant hypertension and that the way these drugs are used in clinical practice may be more likely to result in elevated S-K with enalapril.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1450094     DOI: 10.1007/bf00055607

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  15 in total

1.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1988-05

2.  Long-term prognosis of malignant hypertension; difference between underlying diseases such as essential hypertension and chronic glomerulonephritis.

Authors:  N Kawazoe; T Eto; I Abe; S Takishita; M Ueno; K Kobayashi; K Uezono; H Muratani; Y Kimura; Y Tomita
Journal:  Clin Nephrol       Date:  1988-02       Impact factor: 0.975

3.  Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure.

Authors:  M T Zanella; E Mattei; S A Draibe; C E Kater; H Ajzen
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

4.  Hyperkalemia with enalapril in advanced renal failure.

Authors:  J L Izzo; P S Larrabee; J D Scandling
Journal:  JAMA       Date:  1986-05-16       Impact factor: 56.272

5.  Pathophysiology in malignant hypertension: with special reference to the renin-angiotensin system.

Authors:  N Kawazoe; T Eto; I Abe; S Takishita; M Ueno; K Kobayashi; K Uezono; H Muratani; Y Kimura; Y Tomita
Journal:  Clin Cardiol       Date:  1987-09       Impact factor: 2.882

6.  Deterioration of renal function and hyperkalemia in hypertensive patients with impaired renal function during captopril administration.

Authors:  K Kodama; Y Morotomi; O Kida; T Higa; N Someya; K Kondo; K Tanaka
Journal:  Nihon Jinzo Gakkai Shi       Date:  1985-03

7.  Usefulness of orally active angiotensin I converting enzyme inhibitor (SQ 14,225) in the treatment of malignant hypertension.

Authors:  I Abe; T Kawasaki; M Ueno; Y Kawano; K Uezono; M Ogata; N Kawazoe; T Omae; K Fukiyama
Journal:  Fukuoka Igaku Zasshi       Date:  1980-03

Review 8.  Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity.

Authors:  R M Zusman
Journal:  Am J Kidney Dis       Date:  1987-07       Impact factor: 8.860

9.  Comparison of captopril and enalapril in patients with severe chronic heart failure.

Authors:  M Packer; W H Lee; M Yushak; N Medina
Journal:  N Engl J Med       Date:  1986-10-02       Impact factor: 91.245

10.  Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency.

Authors:  P A Abraham; J A Opsahl; C E Halstenson; W F Keane
Journal:  Arch Intern Med       Date:  1988-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.